Zobrazeno 1 - 10
of 13
pro vyhledávání: '"Jim Middelburg"'
Autor:
Jim Middelburg, Marjolein Sluijter, Gaby Schaap, Büşra Göynük, Katy Lloyd, Vitalijs Ovcinnikovs, Gijs G. Zom, Renoud J. Marijnissen, Christianne Groeneveldt, Lisa Griffioen, Gerwin G. W. Sandker, Sandra Heskamp, Sjoerd H. van der Burg, Tsolere Arakelian, Ferry Ossendorp, Ramon Arens, Janine Schuurman, Kristel Kemper, Thorbald van Hall
Publikováno v:
Nature Communications, Vol 15, Iss 1, Pp 1-15 (2024)
Abstract CD3 bispecific antibody (CD3 bsAb) therapy is clinically approved for refractory hematological malignancies, but responses in solid tumors have been limited so far. One of the main hurdles in solid tumors is the lack of sufficient T-cell inf
Externí odkaz:
https://doaj.org/article/36795cab2cda485e96053669065dc63a
Autor:
Jim Middelburg, Soroush Ghaffari, Tom A.W. Schoufour, Marjolein Sluijter, Gaby Schaap, Büsra Göynük, Benedetta M. Sala, Lejla Al-Tamimi, Ferenc Scheeren, Kees L.M.C. Franken, Jimmy J.L.L. Akkermans, Birol Cabukusta, Simone A. Joosten, Ian Derksen, Jacques Neefjes, Sjoerd H. van der Burg, Adnane Achour, Ruud H.M. Wijdeven, Jon Weidanz, Thorbald van Hall
Publikováno v:
Cell Reports, Vol 42, Iss 12, Pp 113516- (2023)
Summary: The immune checkpoint NKG2A/CD94 is a promising target for cancer immunotherapy, and its ligand major histocompatibility complex E (MHC-E) is frequently upregulated in cancer. NKG2A/CD94-mediated inhibition of lymphocytes depends on the pres
Externí odkaz:
https://doaj.org/article/380d9d0a2508416bb76695633b6aeefe
Autor:
Thorbald van Hall, Jim Middelburg, Gerwin Gerhard Wemke Sandker, Evienne Wilbrink, Janneke Molkenboer-Kuenen, Erik Aarntzen, Sandra Heskamp
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 11, Iss 10 (2023)
Background CD3 bispecific antibodies (CD3-bsAbs) require binding of both a tumor-associated surface antigen and CD3 for their immunotherapeutic effect. Their efficacy is, therefore, influenced by the tumor uptake and the extracellular dose. To optimi
Externí odkaz:
https://doaj.org/article/a20cb64dfac3462d8468563a33246239
Autor:
Christianne Groeneveldt, Priscilla Kinderman, Jim Middelburg, Diana JM van den Wollenberg, Ruben L van den Oever, Dana AM Mustafa, Rob Hoeben, Thorbald van Hall, Nadine Van Montfoort
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 8, Iss Suppl 3 (2020)
Externí odkaz:
https://doaj.org/article/e500026e861d4a7cad521c0e9784c249
Autor:
Christianne Groeneveldt, Priscilla Kinderman, Diana J M van den Wollenberg, Ruben L van den Oever, Jim Middelburg, Dana A M Mustafa, Nadine van Montfoort
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 8, Iss 2 (2020)
Background T-cell-engaging CD3-bispecific antibodies (CD3-bsAbs) are promising modalities for cancer immunotherapy. Although this therapy has reached clinical practice for hematological malignancies, the absence of sufficient infiltrating T cells is
Externí odkaz:
https://doaj.org/article/c3d20f94ac3d4a76b0d4b7271cb48045
Autor:
Jim Middelburg, Kristel Kemper, Patrick Engelberts, Aran F. Labrijn, Janine Schuurman, Thorbald van Hall
Publikováno v:
Cancers, Vol 13, Iss 2, p 287 (2021)
Immunotherapy of cancer with CD3-bispecific antibodies is an approved therapeutic option for some hematological malignancies and is under clinical investigation for solid cancers. However, the treatment of solid tumors faces more pronounced hurdles,
Externí odkaz:
https://doaj.org/article/89b2e23257904dc59552d9def0a249ce
Autor:
Jim Middelburg, Marjolein Sluijter, Gaby Schaap, Büşra Göynük, Katy Lloyd, Vitalijs Ovcinnikovs, Gijs Zom, Renoud Marijnissen, Gerwin Sandker, Sandra Heskamp, Sjoerd van den Burg, Tsolere Arakelian, Ferry Ossendorp, Ramon Arens, Janine Schuurman, Kristel Kemper, Thorbald van Hall
CD3 bispecific antibody (CD3 bsAb) therapy is clinically approved for refractory hematological malignancies, but responses in solid tumors have been limited so far. One of the main hurdles in solid tumors is the lack of sufficient T-cell infiltrate.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::53efff7a4d0e88f729b064b35ec9c84b
https://doi.org/10.21203/rs.3.rs-2470572/v1
https://doi.org/10.21203/rs.3.rs-2470572/v1
Autor:
Soroush Ghaffari, Katherine Upchurch-Ange, Susanne Gimlin, Trivendra Tripathi, Marjolein Sluijter, Jim Middelburg, Thorbald van Hall, Jon Weidanz
Publikováno v:
The Journal of Immunology, 208(9), 2246-2255. AMER ASSOC IMMUNOLOGISTS
The NKG2A/HLA-E axis is an immune checkpoint that suppresses immune effector activity in the tumor microenvironment. In mice, the ligand for the NKG2A/CD94 inhibitory receptor is the nonclassical MHC molecule Qa-1b, the HLA-E ortholog, which presents
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d64bc0a09d858a1fdbe70511c97eda01
https://hdl.handle.net/1887/3513362
https://hdl.handle.net/1887/3513362
Publikováno v:
Chemical Communications, 58, 87, pp. 12196-12199
Chemical Communications, 58, 12196-12199
Chemical Communications, 58, 12196-12199
The flexible N-terminal histone tails are a subject of numerous posttranslational modifications, including methylation. We report development of stapled histone peptides bearing trimethyllysine as ligands for epigenetic reader proteins. Stronger or w
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::39855802760f3e9ad515fb090a071d02
https://doi.org/10.1039/d2cc04294k
https://doi.org/10.1039/d2cc04294k
Autor:
Soroush, Ghaffari, Katherine, Upchurch-Ange, Susanne, Gimlin, Trivendra, Tripathi, Marjolein, Sluijter, Jim, Middelburg, Thorbald, van Hall, Jon, Weidanz
Publikováno v:
Journal of immunology (Baltimore, Md. : 1950). 208(9)
The NKG2A/HLA-E axis is an immune checkpoint that suppresses immune effector activity in the tumor microenvironment. In mice, the ligand for the NKG2A/CD94 inhibitory receptor is the nonclassical MHC molecule Qa-1